Corxel Lands $300M PIPE, $377M Total Proceeds in Amanat SPAC Merger
AMAN is trading near its 52-week low of $9.98 (5.2% above the low).
Summary
Corxel Pharmaceuticals is going public by merging with Amanat, and the deal is anchored by an oversubscribed $300 million private investment from healthcare funds, both new and existing investors. Combined with the SPAC trust, the transaction is expected to deliver $377 million in gross proceeds that fund operations through 2029. The money backs CX11, Corxel's once-daily oral GLP-1 pill, which moves into global phase 3 trials after alignment with the FDA; higher-dose phase 1b data is expected in the first half of next year. Only Corxel US and its obesity portfolio are included — Corxel HK and JX10 stay private. The deal follows this morning's definitive agreement announcement and the 8-K/425 filings, and is expected to close in the first half of 2027.
At the time of this announcement, AMAN was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.8M. The 52-week trading range was $9.98 to $10.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.